Michael Carney, MD
Gynecologic Oncology · Honolulu, HINPI 1790893287
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,370 of the $1,846 with a category attached, or 74.2%. Intuitive Surgical accounts for 74.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $1,370, more than ten times the $97 reported in 2019.
Across 18 payments — averaging $102.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Regeneron$201
- Merck$108
- Immunogen, Inc.$72
- Genentech USA, Inc.$42
- Myriad Genetic Laboratories, Inc.$18
- plus $35 from 3 others
Across 37 payments — averaging $10,498 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$240K
- AstraZeneca$149K
What the payments were for
- Travel & lodging$1,37074%
- Food & beverage$45525%
- Education$211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $1,370 |
| Regeneron | 1 | $201 |
| Merck | 6 | $108 |
| Immunogen, Inc. | 1 | $72 |
| Genentech USA, Inc. | 1 | $42 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Novartis | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,340
How this compares
Too few gynecologic oncology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Medroxyprogesterone Acetate | 13 | $498 |
| Prochlorperazine Maleate | 32 | $360 |
| Letrozole | 19 | $280 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 25 | $258 |
| Ondansetron OdtOndansetron | 17 | $170 |
| Ondansetron Hcl | 13 | $152 |
| Levothyroxine Sodium | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Honolulu
- Tiffany LaiHonolulu$3K
- Thanasak SueblinvongHonolulu$2K
- Robert KimHonolulu$2K
- Travis-Riley KorenagaHonolulu$2K
- Jasmin Reyes MoncadaHonolulu$208
- Suzanne JokajtysTripler Army Medical Center$2K
- Amanda JacksonTripler Amc$647
- David AndersonTripler Army Medical Center$326
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.